WO2024097798

WO2024097798 represents a discovery-stage therapeutic program from Vigil Neuroscience (acquired by Sanofi in 2025) focused on the development of agonists targeting the Triggering Receptor Expressed on Myeloid cells 2 (TREM2). TREM2 is a transmembrane receptor primarily expressed on microglia in the central nervous system, where it plays a critical role in sensing damage-associated molecular patterns and regulating microglial functions such as phagocytosis, survival, and inflammatory responses. By activating TREM2, these therapeutics aim to restore or enhance microglial health and neuroprotective activity, which is often impaired in neurodegenerative conditions. This specific entry is identified through patent mining and likely refers to a series of compounds or a specific approach related to TREM2-targeted small molecules for the treatment of various nervous system diseases, rather than a single named clinical candidate.

Other names

Vigil Neuroscience-TREM2-Nervous System DiseasesVigil Neuroscience TREM2 agonist program